DAILY VARIATIONS IN STEADY-STATE PLASMA-CONCENTRATIONS OF CARBAMAZEPINE AND ITS METABOLITES IN EPILEPTIC CHILDREN

被引:23
作者
HARTLEY, R
FORSYTHE, WI
MCLAIN, B
NG, PC
LUCOCK, MD
机构
[1] Paediatric Research Unit, University Department of Paediatrics and Child Health, Leeds
[2] University Department of Paediatrics and Child Health, General Infirmary at Leeds, Leeds, LS2 9NS, D Floor, Clarendon Wing, Belmont Grove
关键词
D O I
10.2165/00003088-199120030-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Total plasma carbamazepine, carbamazepine-10,11-epoxide (CBZ-EP) and 10,11-dihydro-10,11-trans-dihydroxy-carbamazepine (CBZ-DIOL) concentrations were measured during a 24h period in 21 patients receiving carbamazepine monotherapy, in equally divided doses, every 12h. Interdose and diurnal variations in plasma concentrations of parent drug and metabolites were assessed. Carbamazepine and both metabolites showed significant differences in mean 4h postdose plasma concentrations between day and night dosing (p < 0.001). Significant linear correlations were obtained between carbamazepine dose and plasma concentrations of carbamazepine, CBZ-EP and CBZ-DIOL when sampling times were standardised (p < 0.01). Comparisons of plasma concentrations of the parent compound with those of its 2 main metabolites revealed significant linear correlations in all cases (p < 0.01). The effects of daily fluctuations in plasma concentrations of all 3 compounds on their relative concentrations (CBZ-EP:carbamazepine, CBZ-DIOL:carbamazepine and CBZ-DIOL:CBZ-EP) during the 24h period were also determined: the plasma concentration ratios CBZ-EP:carbamazepine and CBZ-DIOL:carbamazepine were significantly related to the dose of carbamazepine at fixed sampling times (p < 0.05, with 1 exception). The large interdose and diurnal variation in plasma carbamazepine concentrations observed in this study (approximately 40% decrease from peak to trough) has important implications both clinically and in relation to therapeutic drug monitoring.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 35 条
[1]   CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL EFFECTS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE - AN UPDATE [J].
BERTILSSON, L ;
TOMSON, T .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :177-198
[2]   CLINICAL PHARMACOKINETICS OF CARBAMAZEPINE [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1978, 3 (02) :128-143
[3]  
BOURGEOIS BFD, 1984, THER DRUG MONIT, V6, P259, DOI 10.1097/00007691-198409000-00001
[4]   CARBAMAZEPINE 10, 11 EPOXIDE CONCENTRATIONS IN EPILEPTICS ON CARBAMAZEPINE ALONE AND IN COMBINATION WITH OTHER ANTI-CONVULSANTS [J].
BRODIE, MJ ;
FORREST, G ;
RAPEPORT, WG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (06) :747-750
[5]   PRELIMINARY OBSERVATIONS OF SERUM CARBAMAZEPINE CONCENTRATION IN EPILEPTIC PATIENTS [J].
CEREGHINO, JJ ;
VANMETER, JC ;
BROCK, JT ;
PENRY, JK ;
SMITH, LD ;
WHITE, BG .
NEUROLOGY, 1973, 23 (04) :357-366
[6]  
DIEHL LW, 1976, INT J CLIN PHARM BI, V14, P144
[7]   PLASMA-LEVELS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE DURING TREATMENT OF EPILEPSY [J].
EICHELBAUM, M ;
BERTILSSON, L ;
LUND, L ;
PALMER, L ;
SJOQVIST, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 9 (5-6) :417-421
[8]   FACTORS INFLUENCING SIMULTANEOUS CONCENTRATIONS OF TOTAL AND FREE CARBAMAZEPINE AND CARBAMAZEPINE-10, 11-EPOXIDE IN SERUM OF CHILDREN WITH EPILEPSY [J].
ELYAS, AA ;
PATSALOS, PN ;
AGBATO, OA ;
BRETT, EM ;
LASCELLES, PT .
THERAPEUTIC DRUG MONITORING, 1986, 8 (03) :288-292
[9]  
FORSYTHE WI, 1979, DEV MED CHILD NEUROL, V21, P441
[10]  
FORSYTHE WI, 1984, DEV MED CHILD NEUROL, V26, P742